Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Trans-resveratrol

Trans-Resveratrol · also known as Trans-resveratrol, Japanese knotweed extract

In laboratory experiments, resveratrol can affect pathways including SIRT1, AMPK-PGC-1α and NF-κB. Randomized human trials give some evidence of lower NF-κB activity, but direct activation of SIRT1 is disputed, and human results for mitochondrial biogenesis and Nrf2-related effects are inconsistent.

Typical dose: Micronized trans-resveratrol 250–500 mg/day, taken in the morning with a little healthy fat.
Absorption and forms: Trans-resveratrol is the common active form. Light can convert it to the cis form. The cis form may have different activity and effects, so it should not be treated as simply inactive. It is absorbed after oral intake, but blood levels are mainly conjugated metabolites. Systemic exposure to the unconjugated parent compound is low, and levels vary widely between tissues.

Clinical uses and human evidence

Osteoarthritis pain

BeneficialGrade B · Moderate evidence
Studies (1)
  1. Hussain 2018 · Clin Interv Aging · RCT · n=110 — Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study

High blood pressure

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Gu 2022 · Int J Clin Pract · Meta-analysis · n=1151 — Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
  2. Shen 2026 · In Vivo · Meta-analysis · n=2551 — Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases

Blood sugar and insulin resistance

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Zeraattalab-Motlagh 2021 · Am J Clin Nutr · Systematic review — The effects of resveratrol supplementation in patients with type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease: an umbrella review of meta-analyses of randomized controlled trials
  2. Shen 2026 · In Vivo · Meta-analysis · n=2551 — Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases

High LDL cholesterol

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Li 2024 · Prostaglandins Other Lipid Mediat · Meta-analysis — Efficacy of resveratrol supplementation on lipid profile parameters: An umbrella of meta-analysis
  2. Shen 2026 · In Vivo · Meta-analysis · n=2551 — Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases

High triglycerides

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Li 2024 · Prostaglandins Other Lipid Mediat · Meta-analysis — Efficacy of resveratrol supplementation on lipid profile parameters: An umbrella of meta-analysis

Body weight and body fat

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Abu-Zaid 2025 · Eat Weight Disord · Meta-analysis — The effect of resveratrol supplementation on obesity indices: a critical umbrella review of interventional meta-analyses
  2. Shen 2026 · In Vivo · Meta-analysis · n=2551 — Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases

Fatty liver and liver enzymes

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Jakubczyk 2020 · Nutrients · Meta-analysis — Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease-A Meta-Analysis
  2. Shen 2026 · In Vivo · Meta-analysis · n=2551 — Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases

Inflammation markers (such as CRP)

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Rahmati 2026 · Inflammopharmacology · Meta-analysis — Effects of resveratrol supplementation on inflammatory and oxidative stress biomarkers in metabolic disorders: a systematic review and dose-response meta‑analysis of randomized controlled trials

Mechanisms of action

Inhibition of NF-κB / AP-1, the master switches of pro-inflammatory transcription

★★★☆☆Mechanism evidence: grade ASecondary target

Randomized human trials at usual doses observed lower NF-κB activity, but results differ across populations and markers. The upstream mechanism of this effect has not been established, and the finding does not show that SIRT1 directly deacetylates NF-κB p65.

References (3)
  1. Faghihzadeh et al. 2014 · Human randomized placebo-controlled trial: in patients with fatty liver, 500 mg/day for 12 weeks lowered NF-κB activity compared with placebo
  2. Samsami-Kor et al. 2015 · Human randomized placebo-controlled trial: in patients with ulcerative colitis, 500 mg/day for 6 weeks lowered NF-κB activity in peripheral blood mononuclear cells
  3. Saldanha et al. 2016 · Human randomized crossover trial: in patients with chronic kidney disease, 500 mg/day for 4 weeks did not significantly change NF-κB gene expression

AMPK sensing of cellular energy deficit and metabolic reprogramming

★★☆☆☆Mechanism evidence: grade ASecondary target

A human randomized crossover trial observed muscle AMPK activation after 150 mg/day, but another randomized trial did not reproduce it. This may be a weak, indirect effect that depends on context.

References (2)
  1. Timmers et al. 2011 · Human randomized crossover trial: muscle AMPK activation was observed directly after 150 mg/day
  2. Poulsen et al. 2013 · Human randomized trial: did not reproduce the change in muscle AMPK phosphorylation

Sirtuin-dependent protein deacetylase activation

★★☆☆☆Mechanism evidence: grade BSecondary target

Direct allosteric activation of SIRT1 varies with the substrate used in testing, and the conclusions remain disputed. SIRT1 protein can increase in humans, but more protein does not mean higher enzyme activity. Evidence for indirect effects, such as those through phosphodiesterase inhibition, is also insufficient at usual doses in humans.

References (5)
  1. Pacholec et al. 2010 · In-vitro enzyme study: results differed from those of Hubbard et al.; direct activation depended on the test substrate and its hydrophobic residues
  2. Hubbard et al. 2013 · In-vitro enzyme study: results differed from those of Pacholec et al.; direct activation depended on the test substrate and its hydrophobic residues
  3. Price et al. 2012 · Mouse study: some metabolic and mitochondrial responses depended on SIRT1, but this does not show direct binding and activation of SIRT1 in humans
  4. Bo et al. 2018 · Human randomized trial: SIRT1 protein increased in the 500 mg/day group; the link between H3K56 acetylation changes and SIRT1 comes from a post hoc stratified analysis
  5. Williams et al. 2014 · Human randomized crossover trial: after a single 300 mg dose, muscle nuclear SIRT1 activity and p53 acetylation did not change significantly

PGC-1α-driven mitochondrial biogenesis and proliferation

★★☆☆☆Mechanism evidence: grade BSecondary target

In some human studies, PGC-1α protein rose, but mitochondrial content did not increase with it, and changes in respiratory function do not on their own prove mitochondrial biogenesis. In humans, SIRT1-mediated mitochondrial biogenesis and its upstream mechanisms remain uncertain.

References (3)
  1. Timmers et al. 2011 · Human randomized crossover trial: after 150 mg/day for 30 days, muscle PGC-1α protein and citrate synthase activity rose, but mitochondrial content did not change
  2. Alway et al. 2017 · Human randomized trial of resveratrol plus exercise: at 500 mg/day with exercise, the group-by-time interaction for mitochondrial volume density was not significant
  3. Price et al. 2012 · Mouse study: mitochondrial biogenesis and functional changes were observed, and these were SIRT1-dependent

Nrf2/ARE activation of endogenous antioxidant enzymes

★★☆☆☆Mechanism evidence: grade BSecondary target

Some studies suggest resveratrol has Nrf2-related effects, and NQO1 changed in a small human tissue study, but the pathway and dose dependence are still unclear. Human evidence for resveratrol alone is inconsistent. Changes in SOD or Nrf2 gene expression are not enough on their own to prove ARE activation.

References (4)
  1. Cai et al. 2015 · Small human tissue study: in the 5 mg/day group, NQO1 in colorectal mucosa was higher than in untreated controls; the 1 g/day group did not show the same result
  2. Ghanim et al. 2011 · Human controlled crossover trial: a combination of resveratrol and grape polyphenols increased Nrf2 binding to target sequences and NQO1 expression, but this cannot be attributed to resveratrol alone
  3. Seyyedebrahimi et al. 2018 · Human randomized trial: Nrf2 and SOD gene expression rose in peripheral blood mononuclear cells in the 800 mg/day group
  4. Saldanha et al. 2016 · Human randomized crossover trial: 500 mg/day for 4 weeks did not significantly change Nrf2 expression or antioxidant markers in patients with chronic kidney disease

Safety and drug interactions

Resveratrol has weak phytoestrogen-like activity, so people with estrogen-sensitive tumors should be careful. It can inhibit hepatic drug-metabolizing enzymes such as CYP3A4 and CYP2C9. Human probe-drug studies also found CYP2D6 inhibition and CYP1A2 induction. Drug interactions should be treated as a potential risk, but the size of the real clinical effect is not clear. Resveratrol has antiplatelet activity. Combined with anticoagulant or antiplatelet drugs such as warfarin or clopidogrel, it may raise bleeding risk, and it should be stopped 1–2 weeks before surgery. High doses (≥1 g/day) often cause gastrointestinal effects such as diarrhea. Safety data in pregnancy and lactation are insufficient, so people in these groups should check with a doctor first. Higher-dose human trials (in people with fatty liver) reported raised transaminases, so those results should not be applied directly to judging safety at usual doses.

Additive bleeding risk

Has antiplatelet activity. Each of these has a mild antiplatelet or fibrinolytic effect. Alone, the effect is usually small, but when several are combined, the tendency to bleed becomes more noticeable. Stop them 1–2 weeks before surgery or a tooth extraction, and watch for gum bleeding or more bruising.

Inhibition of drug metabolism (CYP3A4 and others)

Inhibits CYP3A4 and CYP2C9. Each of these can inhibit the liver enzymes that metabolize drugs (mainly CYP3A4) or drug transporter proteins, raising blood levels of some prescription drugs.

With Tamoxifen / aromatase inhibitors Note

Tamoxifen, letrozole, anastrozole

Weak estrogen-like activity. People with hormone-sensitive tumors should use caution.

Open in the interactive app ›